Anchiano Therapeutics Ltd - ADR

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock price of Anchiano Therapeutics Ltd. (Nasdaq: ANCN) increased by over 30% pre-market.

ANCN Stock Price Increases Over 30% Pre-Market: Why It Happened

Anchiano s hareholders approve all resolutions at shareholder meeting

Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing

Immunovant Inc

OpGen

Immunovant, Inc. (NASDAQ: IMVT), Anchiano Therapeutics Ltd. (NASDAQ: ANCN) and OpGen, Inc. (NASDAQ: OPGN) are among the biggest healthcare gainers on Monday.

Why Immunovant, Anchiano, OpGen Are Rallying Today

Anchiano Therapeutics (ANCN) stock is rocketing higher on Monday after a shareholder letter caught the interest of investors. The post ANCN Stock: Speculation Around Investor Letter Sends Anchiano Therapeutics Soaring appeared first on InvestorPlace.

ANCN Stock: Speculation Around Investor Letter Sends Anchiano Therapeutics Soaring

The stock price of Anchiano Therapeutics Ltd (NASDAQ:ANCN) increased by over 100% pre-market. This is why it happened.

ANCN Stock Price Increases Over 100% Pre-Market: Why It Happened

The stock price of Anchiano Therapeutics Ltd (NASDAQ: ANCN) increased by 184.29%. This is why it happened.

ANCN Stock Price Increased 184.29%: Why It Happened

ANCN stock is an early stage company engaged in clinical trials for rare liver, lung and skin diseases with no FDA-approved options now. The post ANCN Stock: 10 Things to Know as Anchiano Therapeutics Rockets Higher appeared first on InvestorPlace.

ANCN Stock: 10 Things to Know as Anchiano Therapeutics Rockets Higher

Cardtronics

Change Healthcare Inc

CounterPath

NEW YORK, Feb. 4, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th Floor...

SHAREHOLDER ALERT: WeissLaw LLP Reminds CHNG, CPAH, CATM, and ANCN Shareholders About Its Ongoing Investigations

NEW YORK, Dec. 24, 2020 /PRNewswire/ -- Anchiano Therapeutics Ltd. (NASDAQ: ANCN) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of ANCN with Chemomab Ltd. ANCN shareholders will only receive 10% of the combined...

Lifshitz Law Firm, P.C. Announces Investigation of ANCN, BEAT, HMSY, SNCA, SPWH, TCP, TRP, TLRY, and APHA

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Anchiano Therapeutics Ltd. ("Anchiano" or the "Company") (NASDAQ: ANCN) in connection with the Company's proposed merger with...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd.

Anchiano Therapeutics (ANCN) stock is soaring higher on Tuesday following news of a merger with Chemomab that will bring major changes. The post ANCN Stock: Why Anchiano Therapeutics Stock Is Blasting Higher Today appeared first on InvestorPlace.

ANCN Stock: Why Anchiano Therapeutics Stock Is Blasting Higher Today

Titan Medical Inc

cbdMD Inc

Zhongchao

As of Dec. 10, the GuruFocus All-in-One Screener, a Premium feature, found that the following health care companies have low price-earnings ratios and are owned by gurus. While some of them are great value investments, others may need to be researched more carefully, according to the discounted cash flow calculator.

6 Health Care Stocks Trading With Low Price-Earnings Ratios

Anchiano Therapeutics Ltd. Sponsored ADR (ANCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

All You Need to Know About Anchiano Therapeutics Ltd. Sponsored ADR (ANCN) Rating Upgrade to Buy

CAMBRIDGE, Mass., May  05, 2020  (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr. DiPalma has served as a Senior Financial Advisor to Anchiano by agreement with Danforth Advisors since 2018; he will succeed Jonathan Burgin, who is leaving the Company as part of the planned closure of the Company’s Israel offices and facilities. Mr. Burgin will remain in the position of Chief Operating Officer until the final closure of the Israeli offices and facilities on May 31, 2020. The Company also entered into a consulting agreement with Mr. Burgin, pursuant to which Mr. Burgin agreed to support the financial, accounting and treasury functions of the Company following his departure.

Anchiano Appoints Steve DiPalma as Chief Financial Officer

CAMBRIDGE, Mass., Jan.  17, 2020  (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) to be held on or about March 23, 2020.  The matters raised by Access Industries Holdings LLC and Clal Biotechnology Industries Ltd. will be addressed at the Annual Meeting.  Holders of the Company’s ordinary shares and holders of the Company’s American Depositary Shares at the close of business on February 17, 2020, the record date, will be entitled to receive notice of, and to vote at, the Annual Meeting.

Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders

News for Anchiano Therapeutics Ltd - ADR Stock (ANCN)